Literature DB >> 27735028

Improvement of serum adiponectin and leptin concentrations: effects of a low-calorie or isocaloric diet combined with metformin or orlistat - a prospective randomized open-label trial.

A Kargulewicz1, M Szulińska, M Kujawska-Łuczak, E Swora-Cwynar, K Musialik, M Grzymisławska, M Kręgielska-Narożna, P Bogdański.   

Abstract

OBJECTIVE: We compared the effects of three weight loss interventions on serum concentrations of adiponectin and leptin in obese premenopausal women. PATIENTS AND METHODS: 114 obese Caucasian women were randomized into three groups receiving a low-calorie diet (LC; n = 39), an isocaloric diet with 500 mg of metformin twice a day (IM; n = 38), and an isocaloric diet with 120 mg of orlistat three times a day (IO; n = 37), for three months. Serum concentrations of adiponectin and leptin were evaluated, along with anthropometric and body composition parameters, at baseline and after the study.
RESULTS: Both IO and LC, but not IM, caused an increase in serum adiponectin concentration (p < 0.01, p < 0.05 respectively). A decrease in serum leptin level was documented in the LC (p < 0.001), IM (p < 0.01), and IO group (p < 0.01). Beneficial changes in anthropometric and body composition values were observed following all interventions with the greatest advantage seen in the IO group. The strongest correlations, of Δadiponectin with Δbody weight (r = -0.54), ΔBMI (r = -0.49), ΔFAT [%] (r = -0.48), ΔFAT [kg] (r = -0.48), and Δlean [%] (r = 0.48); and of Δleptin with Δbody weight, ΔBMI, Δwaist, Δfat, and Δlean, were documented in the IO group.
CONCLUSIONS: Beneficial effects were observed on serum leptin concentration, weight loss, and body composition for all interventions and in all examined groups, with the greatest advantage being associated with the orlistat treatment. Improvements in serum adiponectin concentrations resulted from the low-calorie and isocaloric diets with orlistat, but not from the isocaloric diet with metformin. We find these strategies more promising for the treatment of obesity and its related complications in obese premenopausal women.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27735028

Source DB:  PubMed          Journal:  Eur Rev Med Pharmacol Sci        ISSN: 1128-3602            Impact factor:   3.507


  6 in total

1.  Broccoli microgreens juice reduces body weight by enhancing insulin sensitivity and modulating gut microbiota in high-fat diet-induced C57BL/6J obese mice.

Authors:  Xiangfei Li; Shuhua Tian; Yunfan Wang; Jie Liu; Jing Wang; Yingjian Lu
Journal:  Eur J Nutr       Date:  2021-04-17       Impact factor: 5.614

2.  Commentary: Baseline adiponectin concentration and clinical outcomes among patients with diabetes and recent acute coronary syndrome in the EXAMINE trial.

Authors:  Jan Brož; Marek Brabec; Milan Kvapil; Jan Polák
Journal:  Front Endocrinol (Lausanne)       Date:  2018-04-03       Impact factor: 5.555

3.  Prevalence and factors associated with nonalcoholic fatty pancreas disease and its severity in China.

Authors:  Siying Weng; Jianyang Zhou; Xiabo Chen; Yihong Sun; Zhujun Mao; Kefu Chai
Journal:  Medicine (Baltimore)       Date:  2018-06       Impact factor: 1.889

Review 4.  Cancer and comorbidity: The role of leptin in breast cancer and associated pathologies.

Authors:  Amitabha Ray
Journal:  World J Clin Cases       Date:  2018-10-26       Impact factor: 1.337

5.  Metformin coordinates osteoblast/osteoclast differentiation associated with ischemic osteonecrosis.

Authors:  See-Hyoung Park; Mi-Ae Kang; Young Jae Moon; Kyu Yun Jang; Jung Ryul Kim
Journal:  Aging (Albany NY)       Date:  2020-02-11       Impact factor: 5.682

6.  Impact of thoracic paravertebral block combined with general anesthesia on postoperative cognitive function and serum adiponectin levels in elderly patients undergoing lobectomy.

Authors:  Haihui Xie; Jianping Zhou; Wei Du; Shu Zhang; Runcheng Huang; Qi Han; Qingcong Guo
Journal:  Wideochir Inne Tech Maloinwazyjne       Date:  2019-11-05       Impact factor: 1.195

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.